Cancer

News

Roche fights off biosimilar competition as new medicines' sa...

Roche has seen its pharmaceutical sales increase in 2019 as it fought off the impact of cheaper near-copies of its most successful drugs with a batch of new medicines.

News

Pfizer disappoints in Q4 after Ibrance misses sales targets

Pfizer kicked off big pharma’s final results season with a disappointing readout that sent its share price ticking down, with breast cancer drug Ibrance missing sales expectations and off-p

News

Pfizer launches biosimilars to Roche's 'big three' cancer dr...

Pfizer has announced the launch of its competitors to Roche’s ‘big three’ cancer drugs in the US, at a “substantially discounted price” compared with the originators.

News

FDA approves Epizyme's Tazverik in sarcoma

The US regulator has approved Epizyme’s Tazverik (tazemetostat) for advanced sarcoma, providing a new option for a disease where there are high recurrence rates and toxicity issues with est

News

NHS patients denied new lung cancer drug after another NICE ...

Certain untreated lung cancer patients on England's NHS will have to make do with older drugs after NICE ruled in final guidance that AstraZeneca’s Tagrisso (osimertinib) is not cost-effect

News